Verenium Corp

Verenium — Q2 2012 Earnings Presentation

10 slides from Verenium's earnings presentation, Aug 6, 2012

  1. Slide 1: Verenium Corporation Q2 2012 Earnings Call

    Exhibit 99.2 Verenium Corporation Q2 2012 Earnings Call August 6, 2012

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements Statements in this presentation that are not strictly historical are “forward-looking” and involve a high degree of risk and uncertainty. These include, but are not limited to, statements related to Verenium’s technology, products and product candidates (including Verenium

  3. Slide 3: Agenda

    Agenda 1) Janet Roemer, Chief Operating Officer – Second Quarter Commercial Operational Trends & Performance 2) Jeff Black, Chief Financial Officer – Financial Results for the First Half of 2012 3) James Levine, President & Chief Executive Officer – Key Growth Drivers Including: i. Current Commercia

  4. Slide 4: Unique Commercial Products

    Verenium’s Unique Commercial Products Near-term revenue growth driven from share gain in existing markets ANIMAL HEALTH AND NUTRITION Lead Product, $310M+ Market GRAIN PROCESSING $400M Market OILFIELD SERVICES Up to $270M* Combined Market In Hydraulic Fracturing & Filter Cake Removal Source: Market

  5. Slide 5: Product Pipeline

    Verenium’s Product Pipeline (As of Q2 2012) Product Candidate Potential Market Estimated Target Market Size (2016)* Launch Position Animal Health & Nutrition Enzymes Next-Gen Phytase $400 - 450M 2013 - 2015 Major(1) NSP Cocktail $200 - 250M 2013 - 2015 Major (Non Starch Polysaccharides) Grain Proces

  6. Slide 6: Expansion Pipeline: Targeted Markets

    Verenium’s Expansion Pipeline: Targeted Markets Current Markets ANIMAL HEALTH GRAIN PROCESSING OILFIELD SERVICES New Markets BAKING SWEETENERS PERSONAL CARE DETERGENTS /CLEANERS 6

  7. Slide 7: Verenium as a Preferred Collaboration Partner in Industrial Enzymes

    Verenium as a Preferred Collaboration Partner in Industrial Enzymes • OUR TECHNOLOGY Industry leading technology for discovering and evolving enzymes • OUR FULL SUITE OF CAPABILITIES From enzyme discovery, evolution, expression through to commercial scale manufacturing • OUR TRACK RECORD Demonstrate

  8. Slide 8: The Diversified Company We Are Building

    The Diversified Company We Are Building Expansion $2.5B+ market Pipeline opportunity from new potential products for: •Animal Health & Nutrition Product •Oilfield Services Pipeline and •Grain Processing Current •Detergents & Cleaners Commercial •Syrups & Sweeteners Current Products •Personal Care Co

  9. Slide 9: Growth Drivers: Core Technology and Assets

    Verenium’s Growth Drivers Core Technology and Assets Commercial Products Product Pipeline Expansion Pipeline • 8 currently targeted at 3 • 10 new product • Identified candidates under markets Product candidates Pipeline for currently discussion with potential •Animal Health & addressed markets colla

  10. Slide 10: Verenium Corporation Q2 2012 Earnings Call

    Verenium Corporation Q2 2012 Earnings Call August 6, 2012

Verenium — Q2 2012 Earnings Presentation on 6ix